Shazhan Amed, Jeffrey N. Bone, Shreya B. Kishore, Qian Zhang, Joseph Leung
{"title":"A longitudinal cohort study describing childhood type 1 diabetes incidence and prevalence rates in British Columbia, Canada over 27 years (1997–2023)","authors":"Shazhan Amed, Jeffrey N. Bone, Shreya B. Kishore, Qian Zhang, Joseph Leung","doi":"10.1111/dme.70133","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>Our study described incidence and prevalence trends of type 1 diabetes in children and youth under 20 years of age from 1997 to 2023 in the Canadian province of British Columbia (BC) and assessed for a 4-, 5-, or 6-year cyclicity or increase in incidence during the COVID-19 pandemic.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Using linked population-level databases and a validated case-finding and diabetes differentiating algorithm, we identified children with type 1 diabetes diagnosed between 1997 and 2023. Data sources included hospital admissions, outpatient physician visits, and dispensed prescriptions. Population denominators were based on annual age- and sex-stratified population estimates. We calculated incidence per 100,000 and prevalence per 100 cases, using JoinPoint regression to identify trend changes. Cyclical patterns were tested using sine and cosine terms.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>From 1997 to 2023, the incidence of paediatric type 1 diabetes increased markedly until 2008 and then declined very gradually, with similar patterns across age and sex. Incidence was higher in boys, highest among children aged 5 to 14 years, and lowest in those aged 15 to 19 years. After 2012, prevalent cases stabilized in those under 10 and decreased in those over 10 years old. There was no evidence of cyclical trends or changes in incidence or prevalence during or after the COVID-19 pandemic.</p>\n </section>\n \n <section>\n \n <h3> Conclusions/Interpretation</h3>\n \n <p>We report a stabilization of type 1 diabetes incidence and prevalence, along with the absence of pandemic-related increases. These trends may in part reflect demographic changes in British Columbia's paediatric population, including a growing proportion of children from immigrant backgrounds with historically lower type 1 diabetes risk. Unfortunately, our data sources do not include ethnicity, limiting our ability to explore these patterns directly. This study will support the optimization of resource allocation and inform healthcare improvement and long-term management of childhood type 1 diabetes.</p>\n </section>\n </div>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":"42 11","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.70133","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetic Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dme.70133","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Aims
Our study described incidence and prevalence trends of type 1 diabetes in children and youth under 20 years of age from 1997 to 2023 in the Canadian province of British Columbia (BC) and assessed for a 4-, 5-, or 6-year cyclicity or increase in incidence during the COVID-19 pandemic.
Methods
Using linked population-level databases and a validated case-finding and diabetes differentiating algorithm, we identified children with type 1 diabetes diagnosed between 1997 and 2023. Data sources included hospital admissions, outpatient physician visits, and dispensed prescriptions. Population denominators were based on annual age- and sex-stratified population estimates. We calculated incidence per 100,000 and prevalence per 100 cases, using JoinPoint regression to identify trend changes. Cyclical patterns were tested using sine and cosine terms.
Results
From 1997 to 2023, the incidence of paediatric type 1 diabetes increased markedly until 2008 and then declined very gradually, with similar patterns across age and sex. Incidence was higher in boys, highest among children aged 5 to 14 years, and lowest in those aged 15 to 19 years. After 2012, prevalent cases stabilized in those under 10 and decreased in those over 10 years old. There was no evidence of cyclical trends or changes in incidence or prevalence during or after the COVID-19 pandemic.
Conclusions/Interpretation
We report a stabilization of type 1 diabetes incidence and prevalence, along with the absence of pandemic-related increases. These trends may in part reflect demographic changes in British Columbia's paediatric population, including a growing proportion of children from immigrant backgrounds with historically lower type 1 diabetes risk. Unfortunately, our data sources do not include ethnicity, limiting our ability to explore these patterns directly. This study will support the optimization of resource allocation and inform healthcare improvement and long-term management of childhood type 1 diabetes.
期刊介绍:
Diabetic Medicine, the official journal of Diabetes UK, is published monthly simultaneously, in print and online editions.
The journal publishes a range of key information on all clinical aspects of diabetes mellitus, ranging from human genetic studies through clinical physiology and trials to diabetes epidemiology. We do not publish original animal or cell culture studies unless they are part of a study of clinical diabetes involving humans. Categories of publication include research articles, reviews, editorials, commentaries, and correspondence. All material is peer-reviewed.
We aim to disseminate knowledge about diabetes research with the goal of improving the management of people with diabetes. The journal therefore seeks to provide a forum for the exchange of ideas between clinicians and researchers worldwide. Topics covered are of importance to all healthcare professionals working with people with diabetes, whether in primary care or specialist services.
Surplus generated from the sale of Diabetic Medicine is used by Diabetes UK to know diabetes better and fight diabetes more effectively on behalf of all people affected by and at risk of diabetes as well as their families and carers.”